Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Leberl, R. Chen, Z. Moumen, M. Zamora, L. Taraseviciene-Stewart (Aurora, St. Louis, United States Of America). Human apyrase (APT102) treatment attenuates the development of severe pulmonary arterial hypertension (PAH). Eur Respir J 2013; 42: Suppl. 57, 488

Member's Comments

No comment yet.

Related content which might interest you: Therapeutic potential of DMHCA for pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Targeting aquaporin 1 reverses hypoxia-induced pulmonary hypertension in mice Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Expression and function of aquaporin 1 in hypoxia-induced pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Role of survivin in experimental models of pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Effect of POL6014, a protein epitope mimetic (PEM) neutrophil elastase inhibitor, in a model of monocrotaline (MCT)-induced pulmonary arterial hypertension in rats Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Renal denervation reduces pulmonary vascular remodeling in two experimental pulmonary arterial hypertension models Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Erythropoietin recapitulates hemodynamic features of hypoxia-induced pulmonary hypertension in mice Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Formation of typical vascular lesions in a new experimental model of pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Role of the TrkA receptor in experimental severe pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Intact serotonin signaling is not required for the development of severe angioproliferative pulmonary hypertension in rats Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Role of tadalafil in patients with hypoxia / lung disease induced (group 3) pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Repeated embolization and fibrinolysis inhibition induce chronic thromboembolic pulmonary hypertension in rabbits Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013 Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Immunity in idiopathic pulmonary arterial hypertension (IPAH), a role for activated DCs? Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Phosphodiesterase inhibitors as promising therapies for cigarette smoke-induced emphysema and pulmonary hypertension (PH) in mice Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Selective inhibition of neutrophil elastase by BAY 85-8501 improves exercise capacity and pulmonary hypertension in a porcine pancreatic elastase-induced emphysema model Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016 Blunted effects of rho-kinase inhibitor, fasudil, on pulmonary arterial pressure in Yak, a high altitude-adapted animal Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Effects of pulmonary rehabilitation (PR) in idiopathic pulmonary arterial hypertension (PAHI) Source: Annual Congress 2013 –The latest insights in pulmonary rehabilitation (part 2) Year: 2013